Abstract 23P
Background
Lung cancer is a leading cause of mortality globally, particularly the subtype called lung adenocarcinoma (LUAD). Current treatments have limited success, emphasizing the need for better therapies. Heparan sulfate proteoglycans (HSPGs) and heparanase (Hpse) play important roles in cancer progression, including LUAD, but their exact functions are not fully understood. Our study aims to explore Hpse's relevance in LUAD progression and its effects on tumor cells.
Methods
We introduced shRNAs by lentiviral transfections against heparanase into a murine and a human cell line. We performed intravenous and orthotopic injections to assess the effects of our genetic perturbations on tumor growth, survival, and the tumor immune microenvironment.
Results
The study investigated the correlation between heparanase mRNA expression and overall survival in LUAD patients. Using the PRECOGG database and the Cancer Genome Atlas, we found that elevated HPSE expression correlated with poor overall survival in LUAD patients. Additionally, in vitro experiments demonstrated that heparanase promoted migration and invasion of lung cancer cells, suggesting its role in metastasis. Moreover, in vivo studies using mouse models showed that Hpse knockdown reduced tumor growth and metastasis and increased the survival of mice. Spectral flow cytometry analysis revealed many changes in the immune microenvironment between tumors with high and low Hpse expression, with significant alterations in myeloid and lymphoid cell populations. Notably, in Hpsel-low tumors, alveolar macrophages were more abundant. Surprisingly, these macrophages displayed an anti-tumorigenic phenotype characterized based on single-cell sequencing performed on leukocytes.
Conclusions
To conclude, our findings support our clinical analysis revealing that heparanase should be investigated further as a therapeutic target for patients with LUAD. More effort should be put towards inhibitors and trials should focus on this patient population that is in dire need of novel treatment options.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
CIHR.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73P - Effect of combination therapy with atezolizumab plus metformin on peripheral immune cells from NSCLC patients
Presenter: Luisa Amato
Session: Cocktail & Poster Display session
Resources:
Abstract
74P - Obesity regulates tumor progression and sensitivity to checkpoint blockade through the diet-microbiota-immunity axis
Presenter: Lysanne Desharnais
Session: Cocktail & Poster Display session
Resources:
Abstract
75P - Possible significance of the proline at position 325 in the recognition of the MX35 epitope of the NaPi2b transporter by monoclonal antibodies
Presenter: Leisan Bulatova
Session: Cocktail & Poster Display session
Resources:
Abstract
76P - Circadian control of neutrophil extracellular trap formation temporally regulates metastatic lung cancer progression
Presenter: Simon Milette
Session: Cocktail & Poster Display session
Resources:
Abstract
78P - Daily rhythmic expression of pro-tumoral programs in NSCLC shape cancer immunity and therapy response
Presenter: Alba de Juan
Session: Cocktail & Poster Display session
Resources:
Abstract
79P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
80P - Tumor microenvironment (TME) defines prognosis of EGFR-mutant non-small cell lung cancer (NSCLC)
Presenter: Lodovica Zullo
Session: Cocktail & Poster Display session
Resources:
Abstract
81P - Single-cell spatial landscape of NSCLC reveals subtype specific immune features
Presenter: Mark Sorin
Session: Cocktail & Poster Display session
Resources:
Abstract
82P - Tumor cell-released autophagosomes (TRAPs) promote breast cancer lung metastasis by modulating neutrophil extracellular traps formation
Presenter: XIAOHE ZHOU
Session: Cocktail & Poster Display session
Resources:
Abstract
83P - Evaluation of serum macrophage inhibitory cytokine 1 as a diagnostic biomarker for pancreatic cancer: A systematic review and diagnostic accuracy meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract